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ABSTRACT
Introduction: Acute bacterial skin and skin
structure infections (ABSSSIs) remain among
the most common infectious processes seen in
the clinical setting. For patients with complicated ABSSSIs deemed to require intravenous
antibiotics, vancomycin remains the mainstay
therapy. Ceftaroline has been shown to be nonEnhanced digital features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.7825091.
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inferior to vancomycin and may result in faster
resolution of signs of infection.
Methods: Multicenter, prospective, open-label,
randomized trial of ceftaroline versus vancomycin for the treatment of adult patients
admitted for management of ABSSSIs from April
2012 to May 2016; 166 patients in the clinically
evaluable (CE) group were needed to determine
a 20% difference in primary outcome of clinical
response at day 2 or 3 of antibiotics. Clinical
response was defined as cessation of spread of
lesion and improvement in systemic signs/
symptoms of infection. A secondary outcome
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was a C 20% reduction in lesion size at day 2 or
3 of antibiotics.
Results: One hundred seventy-four patients
were enrolled in the intention-to-treat (ITT)
group and 108 were CE. Among CE patients, 54
were randomized to ceftaroline and 54 to vancomycin. Baseline characteristics were similar
except patients in the ceftaroline arm were
older and had a non-significantly higher degree
of comorbidities (median Charlson score 2 vs. 4,
respectively). Cellulitis was the most common
type of ABSSSI (85.2% vs. 79.6%, respectively).
Rapid diagnostic testing of available cultures
(n = 55) demonstrated high agreement with
clinical microbiology for identification of Staphylococcus aureus (100%) and MRSA (100%).
There was no significant difference in primary
outcome of day 2 or 3 clinical response (50.0%
vs. 51.9%).
Conclusion: Early clinical response between
vancomycin- and ceftaroline-treated ABSSSIs
was similar. Patients with ABSSSIs rarely
remained hospitalized for [ 2–3 days, thus limiting our ability to critically assess clinical
outcomes.
Trial Registration: ClinicalTrials.gov identifier,
NCT02582203.
Funding: Allergan plc.
Keywords: Acute bacterial skin and skin
structure infection; Ceftaroline; Methicillinresistant S. aureus; Vancomycin

INTRODUCTION
Acute bacterial skin and skin structure infections (ABSSSIs) are among the most common
infections encountered in the hospital setting
[1–5].
There
are
approximately
600,000–800,000 hospitalizations secondary to
ABSSSIs per year, accounting for 2% of all hospital admissions [5]. The majority of these
infections are treated in the emergency department, with abscess and cellulitis being reported
as the primary infection [4]. Eldelsberg et al. [2],
however, reported that national ABSSSI hospitalizations increased by 29% from 2000 to 2004.
This is particularly significant as hospitalization
for ABSSSI represents a significant cost burden

to the US healthcare system, resulting in
approximately $6 billion per year in inpatient
costs with the average patient stay estimated to
cost $8000 USD per patient. Itani et al. [6]
identified 5156 patient cases of ABSSSIs from
2002 to 2006 for which the average length of
hospital stay and cost of treatment was 9.5 days
and $40,046 dollars, respectively. Patients that
had MRSA compared with non-MRSA cases were
noted to have a significantly longer length of
hospital stay.
Because no newer agent has shown superiority, vancomycin is commonly employed in
the treatment of complicated ABSSSIs and is
recommended as first-line therapy in the
Infectious Disease Society of America (IDSA)
MRSA guidelines and skin and soft tissue
infection guidelines when MRSA is suspected
[7–9]. Since the last edition of the IDSA MRSA
Guidelines in 2011, several new agents have
been approved for the treatment of ABSSSIs,
including those caused by MRSA. Approval
studies for these agents, however, only need to
meet the primary end point of non-inferiority
based on a pre-defined margin [10]. Although
the drug approval trials were designed to prove
non-inferiority, ceftaroline demonstrated a
more rapid time to resolution of symptoms at
day 3 compared with vancomycin in a subset of
patients (n = 797) with lesion size C 75 cm2
and/or a major abscess C 5 cm. This current
study seeks to determine if ceftaroline will result
in more rapid resolution of ABSSSIs in a real-life
cohort of patients [11, 12]. The primary purpose
of this study was to assess clinical outcomes of
ceftaroline versus vancomycin in the treatment
of patients hospitalized with complicated
ABSSSIs with respect to early clinical outcomes.
We additionally estimated the potential economic impact of these two agents by assessing
overall costs.

METHODS
Patient Population and Setting
This study was conducted at three large academic medical centers within the Detroit
metropolitan area: Detroit Medical Center
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(Detroit Receiving Hospital, Harper University
Hospital, Sinai-Grace Hospital, Huron Valley
Sinai Hospital), Henry Ford Hospital, and St.
John’s Hospital. Patients were eligible if: 18–89 years of age; presented to the emergency
department with complicated ABSSSI defined as
wound/surgical site infections, cellulitis, and
major abscesses by FDA guidance; required
parenteral antibiotics; anticipated to be admitted for at least 2 days, were at risk for MRSA, or
had ABSSSI caused by MRSA. Risk factors for
MRSA included prior antibiotic use (60 days to
presentation), prior hospital exposure (180 days
to presentation), presence of skin ulcer; central
venous catheters, and known history of MRSA.
Patients were excluded if any one of the following was present or suspected: gas gangrene,
necrotizing infections, osteomyelitis, complicated bacteremia, endocarditis, and infection
due to a gram-negative pathogen or other grampositive pathogen not identified as Staphylococcus aureus or Streptococcus; known resistance to
ceftaroline and/or vancomycin, treatment of
ABSSSI for C 24 h before enrollment, surgical
incision, and drainage without antibiotics;
requirement for renal replacement therapy; life
expectancy \ 2 month; burn [ 30% body surface area; known allergy to study drug; pregnant
or nursing; or a prisoner at time of randomization. Wayne State Institutional Review Board
(114211MP4F), Henry Ford Institutional Review
Board (9195), and St. Johns Hospital (IRB #
383245-17) approved this trial. All procedures
performed in studies involving human participants were in accordance with the ethical
standards of the institutional and/or national
research committee and with the 1964 Helsinki
Declaration and its later amendments or comparable ethical standards. Informed consent was
obtained from all individual participants included in the study. All study subjects completed
the informed consent process.
Experimental Design
This was a multicenter, prospective, open-label,
randomized trial of ceftaroline versus vancomycin for the treatment of ABSSSI. Patients
were prospectively identified through clinical
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surveillance systems (TheraDocÒ, Salt Lake City,
UT, or SENTRI7, Washington, DC) daily based
on orders of IV vancomycin, ampicillin-sulbactam, or clindamyci, as these were most likely to
have an indication of skin and soft tissue
infection. Informed consent was obtained prior
to the start of study antibiotic. After consent,
patients were randomized (via computerized
random mix block generator nQuery AdvisorÒ
7.0) 1:1 to ceftaroline ± metronidazole or to
vancomycin ± ceftriaxone ± metronidazole or
ampicillin/sulbactam by study site. Ceftaroline
was dosed according to renal function. Vancomycin was dosed according to pharmacy
protocol of each respective institution to a target serum trough concentration of 10–20 mg/l
within the first 72 h. Data were collected using
the REDCap electronic data collection system
[13].
Clinical Data
Prospective data collection included size of the
lesion (cm or cm2) at time of consent and randomization as well as size of the lesion at follow-up (2–3 days). Information extracted from
electronic medical records (eMR) included
demographics and baseline characteristics, primary diagnoses, comorbid conditions (Charlson
comorbidity index), location within the hospital, and duration of hospitalization and ICU
stay. Clinical, laboratory, and radiologic data
related to the infection were also collected,
including microbiologic cultures, duration of
antibacterial therapy, and clinical outcomes
such as resolution of fever and white blood cell
count. In addition to standard clinical microbiology performed as standard of care, polymerase chain reaction-based rapid diagnostic
testing (RDT) was performed on a subgroup of
specimens via Cepheid GeneXpertÒ II MRSA/SA
SSTI Assay (Cepheid Inc., Sunnyvale, CA, USA).
The agreement between RDT and clinical
microbiology S. aureus and MRSA identification
was determined.
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Clinical and Economic Definitions
and Outcomes
The primary outcome of interest was to evaluate
differences in clinical response at day 2 or 3 of
antibiotic therapy between patients receiving
vancomycin
versus
ceftaroline.
Clinical
response was defined as cessation of spread of
lesion (no increase from baseline) and absence
of fever at the early assessment time point.
Secondary clinical outcomes were number of
responders with C 20% reduction of lesion size
at end of day 2 or 3 of study drug and the overall
clinical response as noted by the primary treating physician at the end of inpatient treatment.
Overall clinical response was defined as cure
versus improved versus failure. Cure was resolution of pre-treatment signs and symptoms of
infection with no additional need for antibiotic
therapy. Improved was defined as incomplete
resolution of pretreatment signs and symptoms
and/or need for additional antibiotic therapy.
Failure was defined as persistent signs and
symptoms of infection, a need for change in
antibiotic therapy from study drug, and/or need
for [ 14 days of antibiotic therapy for ABSSSI.
Cost of care was determined by overall length of
stay, which was estimated using 2015 American
Hospital Association total cost estimates [14].
Analysis of clinical outcomes was completed
using the clinically evaluable (CE) patient population. The CE population was defined as all
patients who received at least 48 h of study drug
and had follow-up measurement of their lesion.
Intention-to-treat (ITT) patients were those initially consented and randomized who received
at least one dose of study antibiotic but did not
have follow-up measurement of their lesion.
Statistical Analysis
Assuming a statistical power of 80%, two-sided a
of 0.05, a minimum of 166 CE patients were
needed to detect a 20% difference in primary
clinical outcome. Descriptive statistics were
reported as percentages, means and standard
deviations, or medians with interquartile ranges
(IQRs), as applicable. Dichotomous variables
were compared using Pearson’s chi-squared test

or Fisher’s exact test, as applicable. Continuous
variables were compared using Wilcoxon ranksum test or Student’s t-test, as applicable. Variables with p \ 0.05 were considered statistically
significant. Multivariable backwards-stepwise
logistic regression was performed to determine
variables independently associated with clinical
failure. Variables associated with the primary
outcome upon univariate analysis with p \ 0.1
or determined to be clinically relevant a priori
were included in the model. The Kaplan-Meier
estimator with log-rank statistic was used to
determine time to resolution of fever and normalization of WBC between patients treated
with vancomycin or ceftaroline. Statistical
analysis was performed using IBM SPSS version
22.0 (IBM Corp., Armonk, NY, USA). A post hoc
futility analysis was completed to determine the
necessary sample size to determine statistically
significant differences in the primary clinical
outcome (SAS version 9.4, SAS Institute Inc.,
Cary, NC, USA).

RESULTS
From April 2012 to May 2016, 174 patients were
consented and enrolled; 108 patients met CE
criteria. Among the ITT patients, 82 were randomized to receive ceftaroline and 92 to receive
vancomycin. Of the CE patients, 54 were randomized to ceftaroline and 54 to vancomycin.
The mean age of the entire CE cohort was
51.4 years ± 15.4 years, there were more males
(58, 53.7%), the majority were African American (58, 53.7%), and cellulitis was the most
common type of ABSSSI (89, 82.4%), followed
by abscess (30, 27.8%). Overall, the cohort had a
low level of comorbidity with a median Charlson score of 3 (IQR 1–5). There were no significant differences in baseline characteristics or
measured comorbid conditions with the
exception of age; Charlson score was also
numerically higher in the ceftaroline arm
(Table 1). The majority of patients in both
groups were admitted to medical services
(94.1% vs. 85.7%, p = 0.11). One patient in the
ceftaroline group and zero patients in the vancomycin group were admitted to the ICU. A
total of 44 (40.8%) patients presented with
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Table 1 Baseline demographics and clinical characteristics of the CE population
Characteristic

VAN (n = 54)

CPT (n = 54)

p value

Mean age, years (SD)

48.1 (16.5)

54.8 (13.6)

0.018

Charlson score (IQR)

2 (0–4)

4 (1–5)

0.074

Baseline SCr, mg/dl (IQR)

0.90 (0.77–1.10)

0.97 (0.72–1.28)

0.758

Type of ABSSSI
Cellulitis

43 (79.6)

46 (85.2)

0.448

Abscess

16 (29.6)

14 (25.9)

0.667

2 (3.7)

3 (5.6)

0.674

Upper extremity

6 (11.1)

11 (20.4)

0.186

Lower extremity

36 (66.7)

33 (61.1)

0.548

Abdomen

7 (13.0)

3 (5.6)

0.184

Chest

2 (3.7)

1 (1.9)

0.558

Head/neck

0 (0.0)

1 (1.9)

0.315

2 (3.7)

2 (3.7)

1.000

14 (25.9)

15 (27.8)

0.828

History of ESLD, n (%)

2 (3.7)

1 (1.9)

0.558

IV drug user, n (%)

8 (14.8)

4 (7.4)

0.221

CKD (not HD)

4 (7.4)

8 (14.8)

0.221

History of COPD, n (%)

5 (9.3)

8 (14.8)

0.375

Prosthetic device, n (%)

2 (3.7)

4 (7.4)

0.401

Chronic skin ulcer, n (%)

9 (16.7)

5 (9.3)

0.252

Antibiotics past 30 days, n (%)

7 (13.0)

7 (13.0)

1.000

Prior ABSSSI past 1 year, n (%)

7 (13.0)

11 (20.4)

0.302

19 (35.2)

18 (33.3)

0.839

Surgery past 30 days, n (%)

0 (0.0)

2 (3.7)

0.153

MRSA infection past year, n (%)

1 (1.9)

1 (1.9)

1.000

Wound infection
Site of ABSSSI

History of DM without end organ damage, n (%)
History of DM with end organ damage, n (%)

Prior hospitalization past year, n (%)

SCr serum creatinine, ABSSSI acute bacterial skin and skin structure infection, DM diabetes mellitus, ESDL end-stage liver
disease, IV intravenous, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease
abnormal WBC (35.8% ceftaroline vs. 46.0%
vancomycin, p = 0.3). The median lesion size at
time of randomization in the ceftaroline group
was 236.0 cm2 (IQR 86.6–790.0 cm2) and in the
vancomycin group was 275.0 cm2 (IQR
150.0–675.0 cm2), p = 0.62.

There was no significant difference in primary outcome of day 2 or 3 clinical response
(50.0% vs. 51.9%, p = 0.92). Follow-up lesion
size reduction was not statistically different
between patients who received ceftaroline versus vancomycin [16.7% (IQR 0–30.8%) vs.
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Table 2 Variables associated with clinical failure in multivariable analysis
Factor

Unadjusted OR

95% conﬁdence
interval

Adjusted OR

95% conﬁdence
interval

IV drug use

0.244

0.055–1.080

0.251

0.054–1.159

Charlson score

1.300

1.061–1.592

1.305

1.065–1.599

Prior antibiotics

3.066

1.193–7.878

2.807

0.946–8.332

DM with end organ damage

Removed from model

Vancomycin group

Removed from model

Hosmer-Lemmeshow p = 0.209

15.3% (IQR 1.7–30.8%), p = 0.75]. Of the
patients with an abnormal WBC, there was no
significant difference in mean time to normalization (2.4 ± 0.4 days vs. 1.8 ± 0.2 days).
Additionally, there was no difference in mean
time
to
temperature
normalization
(2.1 ± 0.4 days vs. 1.3 ± 0.1 days). There was
no significant difference in clinical cure/improvement rates at end of ceftaroline or vancomycin inpatient therapy (81.5% vs. 75.6%,
p = 0.64). Upon univariate analysis history of
diabetes with end organ damage, prior antibiotics, IVDU, and Charlson score were associated
with treatment failure. Multivariable binary
logistic regression was performed with treatment group forced into the model, and only a
higher Charlson score was independently associated with clinical failure (Table 2).
The median length of stay in the vancomycin arm was 3.5 days (IQR 3–5 days) versus
4 days (IQR 3–6 days) in the ceftaroline arm,
p = 0.43. The median total cost of care for ceftaroline patients was $5200 USD (IQR
$3900–$7800) versus $4550 (IQR $3900–$6500),
p = 0.93. The majority (71.3%) of patients were
discharged on oral antibiotics to complete their
course of therapy; clindamycin (25.9%), TMP/
SMX (13.0%), and cephalexin (12.0%) were the
most common agents used. There was no significant difference in discharge disposition,
with 79.6% of vancomycin-treated and 85.2%
of ceftaroline-treated patients discharged home
(p = 0.61). Thirty-day infection-related ED
revisits and readmissions were also similar
between the two treatment groups. Only 9.3%

of vancomycin-treated and 5.6% of ceftarolinetreated patients were re-admitted within 30
days of their index visit (p = 0.72).
In the ITT/CE cohort, 55/44 (ITT/CE) organisms were identified via standard clinical
microbiology: 21 patients in the ceftaroline
group and 23 patients in the vancomycin
group. Among CE patients with culture-positive
results, 15 (71.4%) of the isolates in the ceftaroline group and 17 (73.9%) in the vancomycin group were S. aureus. Oxacillin
resistance was identified in 61.1% and 85.7% of
these isolates, respectively. The remainder of
the organisms identified included coagulasenegative staphylococci (9.1%), streptococci spp.
(11.4%), and one Escherichia coli and one Pseudomonas aeruginosa. In addition to the standard
clinical microbiology, polymerase chain reaction (PCR)-based rapid diagnostic testing to
detect MRSA or MSSA was performed on 54 ITT/
CE specimens during the study. When MRSA or
MSSA was isolated by clinical microbiology, the
RDT was correct in all cases, resulting in 100%
agreement. Among 20 non-S. aureus-positive
cultures, the RDT identified S. aureus in 4
(20.0%). All four of these disagreements were
observed in polymicrobial cultures.
A post hoc futility analysis was completed to
determine the necessary sample size to detect a
statistically significant difference in primary
outcome given the observed difference of 1.9%.
To obtain p \ 0.05, 10,989 patients needed to
be clinically evaluable in each treatment arm
(Table 3).
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Table 3 Results of post-hoc futility analysis
Futility analysis

Per group sample size

Total sample size

Lower bound nominal p

Signiﬁcance threshold

1

1558

3116

0.0758

0.92

2

3115

6230

0.1955

0.80

3

4672

9344

0.3565

0.64

4

6229

12,458

0.5295

0.47

5

7786

15,572

0.6872

0.31

6

9343

18,686

0.8122

0.18

7

10,900

21,800

0.8998

0.1

8

12,457

24,914

0.9578

0.04

Need n = 10,989 per group to achieve a 1.9% difference in primary outcome with 80% power at a = 0.05

DISCUSSION
This was a prospective multicenter study evaluating the impact of ceftaroline versus vancomycin for the treatment of patients
hospitalized with ABSSSIs. Over a 4-year period,
we were unable to achieve our initial sample
size of 166 CE patients. One major hindrance to
meeting the a priori sample size was the
changing practices for the management of
ABSSSIs, with treatment moving increasingly to
the outpatient setting [3]. For instance, based
on internal data, treatment of ABSSSIs that initially required hospitalization often resulted in
lengths of stay of 3–5 days, making early test-ofcure analysis challenging. In a previous clinical
evaluation of ABSSSIs in hospitalized patients at
the Detroit Medical Center (DMC), our group
demonstrated improved efficacy and decreased
costs when daptomycin was compared with
vancomycin [15]. Daptomycin achieved more
rapid resolution of infection, a greater overall
clinical cure, shorter mean length of stay (4 vs.
7 days, p \ 0.001) compared with vancomycin.
This difference resulted in a significant ($5027
vs. $7553, p \ 0.001) median cost difference
favoring daptomycin. This study, however, was
conducted a decade ago. In a more recent
pragmatic study comparing vancomycin to
daptomycin for the treatment of ABSSSIs, Kauf
et al. found no significant difference in clinical
success [16]. The likelihood day-2 response was

lower in the vancomycin arm through multivariable regression analysis; this result, however, demonstrated a low degree of precision
and 95% CI close to 1.0 (OR = 0.498, 95% CI
0.249–0.997). Our results demonstrated similar
day 2 and/or 3 clinical responses between vancomycin and ceftaroline and similar overall
patient outcomes requiring a sample size [
20,000 patients to detect a statistically significant, though arguably not clinically significant,
outcome.
During this study, we also had the opportunity to evaluate a polymerase chain reactionbased RDT platform on a subgroup of patients
[17]. The results demonstrate consistent ability
to detect S. aureus and MRSA when present and
are consistent with other evaluations of this
technology demonstrating high sensitivity.
Given the high prevalence of MRSA among
ABSSSIs, the improvement in time to identification via RDT has the potential to rapidly
streamline antibiotic therapy to improve time
to optimal therapy and minimize unnecessarily
broad-spectrum coverage. We did, however,
experience difficulties in using RDTs to assist in
enrolling patients with specific pathogens, in
particular the limited samples that could be run
in a timely manner. Few patients had viable
samples for testing, and timing of collection
may be challenging if the infection was incised
and drained prior to screening. Nonetheless, the
technology demonstrates the potential to assist
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studies in targeting certain patient populations
based on microorganisms identified.
Several limitations need to be addressed.
Although the study was randomized, there were
several imbalances in the patient cohorts. In
particular, patients treated with ceftaroline had
higher Charlson Comorbidity Index scores,
higher rates of CKD, higher rates of prosthetic
involvement, and higher rates of previous
ABSSSIs. Although individually these differences were not statistically significant, taken
together they may account for the trend toward
improved outcomes in vancomycin therapy;
however, the sample size is too small for formal
assessment. Additionally, the study was heavily
weighted toward the treatment of cellulitis as
opposed to wounds or abscesses. Although
patients were required to have risk factors for
MRSA to be enrolled in the study, it is still likely
that the majority of these infections were
caused by streptococci and not S. aureus.
Importantly, 55% of patients included in the
analysis demonstrated response to therapy after
1 day of antibiotics. This finding, coupled with
the fact that patients could receive up to 24 h of
therapy before enrollment, also helps to explain
our findings. Lastly, due to the nature of the
patient population under study, of which many
frequently visit multiple healthcare facilities in
the metro Detroit area, there is the potential to
have missed ED visits or hospitalizations to
facilities outside those included in this study.
Another important consideration is based on
published data demonstrating that early clinical
response is influenced by more than antibiotic
selection [18]. In a recently published study
from Bruun et al., day 2 or 3 response in ABSSSIs
occurred commonly (90% of patients) and was
related to antibiotic therapy, but also other
non-pharmacologic factors such as type of
ABSSSI, duration of symptoms before treatment,
and BMI. The authors recommended a combined clinical and biochemical parameter for
response to therapy. In fact, the results of the
DISCOVER trial have been used to highlight the
lack of clinical relevance of this end point for
determining successful outcomes [19]. This is
not without controversy, however [20]. A
recently published pooled analysis of ESTABLISH trials reported a high predictive value for

clinical cure [20, 21]. Although it is recommended that sustained clinical response
through continued resolution of signs and
symptoms of infection 7–14 days after therapy
should be measured, the patient population of
the Detroit metropolitan area made this followup assessment challenging [22].

CONCLUSION
Early clinical response between vancomycinand ceftaroline-treated ABSSSIs was similar in
this open-label randomized clinical trial. The
majority of patients in this study presented with
cellulitis and were allowed to have up to 24 h of
antibiotic therapy before enrollment, which
may limit generalizability of the current results.
Additionally, patients with ABSSSIs rarely
remained hospitalized for [ 2–3 days, thus limiting our ability to critically assess clinical
outcomes.
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